Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 2Endocrine 2CNS 1

Conditions

Neuroblastoma 2Meningioma 2Medulloblastoma 2Neuroendocrine Tumors 1

Interventions

Magnetic Resonance Spectroscopy 7gallium Ga 68 dotatate 6lutetium Lu 177 dotatate 4Fluorodeoxyglucose F18 33-Iodobenzylguanidine 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3fluorodopa F 18 2Specimen Handling 2FAPI-46 2Everolimus 2Erlotinib Hydrochloride 2vandetanib 1romidepsin 1pertuzumab 1pentetreotide 1olaparib 1fludarabine phosphate 1entrectinib 1dactolisib 1cabozantinib 1atezolizumab 1arginyllysine 1amino-acid, glucose, and electrolyte solution 1alectinib 1Whole Body Imaging 1Tretinoin 1Respiratory Therapy 1Quality of Life 1Positron-Emission Tomography 1Patient Reported Outcome Measures 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Amino Acids × CNS × Clear all
NCT03273712 2023-02-09

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

University of Iowa

Phase 2 Completed
39 enrolled 9 charts
CNSEndocrineNET

Medulloblastoma, Meningioma, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡